When recent Tulane University grad Ishaan Pomichter was taking a digital technology class taught by famed biographer and writer Walter Isaacson last year, the young tech devotee decided to curate a ...
Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that several members of its Board of ...
Cabaletta Bio Kicks Off Pivotal Myositis Trial, Touts Automated CAR-T Manufacturing Path to 2027 BLA
Cabaletta Bio (NASDAQ:CABA) executives told investors at the Guggenheim Emerging Outlook Biotech Summit 2026 that the company has initiated enrollment in what it described as its first pivotal program ...
According to the company, which describes itself as "deeptech", mind-controlled pigeons have several advantages over ...
As U.S.-based Regeneron throws its full weight behind patent lawsuits to extend the monopoly of the macular degeneration blockbuster treatment "Eylea," launches of biosimilars by Korea's bio ...
Nutriband terminated a previously agreed-to sale of its subsidiary Pocono Pharmaceuticals to Earth Vision Bio. Nutriband said Earth Vision failed to pay applicable late fees for not closing the deal ...
Bio-Rad Laboratories Inc. (BIO.B) on Thursday reported fourth-quarter net income of $720 million, after reporting a loss in ...
Bio-Rad trades at nearly 30 times forward earnings despite recent losses, reflecting expectations for a turnaround as its projected EPS growth exceeds 115%. Thursday’s results will test whether that ...
Avant Technologies, Inc. (OTCQB: AVAI) ("Avaí" or the "Company"), an emerging biotechnology company focused on developing cell-based therapies for diabetes and age-related disorders, today announced ...
Michigan biotech gets Series B funding to expand sustainable polymer production replacing synthetic plastic materials ...
Fintel reports that on February 13, 2026, Piper Sandler initiated coverage of Climb Bio (NasdaqGM:CLYM) with a Overweight recommendation. Analyst Price Forecast Suggests 83.87% Upside As of February 4 ...
TrialRelay™, powered by the TrialRouter™ AI agent, replaces passive networks with active orchestration for physician-to-physician handoffs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results